Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  talazoparib
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
Decitabine and Talazoparib in Treating Patients with Untreated Relapsed, or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1565GCC, NCI-2017-00417, NCT02878785
Talazoparib before Standard Therapy in Treating Patients with Invasive, BRCA-Mutated Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0045, NCI-2015-00335, NCT02282345
Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BRS0050, NCI-2015-00036, 350, NCT02401347
Open-Label Extension and Safety Study of Talazoparib
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: MDV3800-13, NCI-2017-00041, NCT02921919
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9782, NCI-2014-02474, NCI 9782, NCT02317874
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Tumors and BRCA Mutations or Triple-Negative Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CC #14955, NCI-2015-00713, 130847, 14955, NCT02358200
Talazoparib and Irinotecan Hydrochloride with or without Temozolomide in Treating Younger Patients with Refractory or Recurrent Solid Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 25
Trial IDs: BMNIRN, NCI-2015-00255, NCI-2015-00215, NCT02392793
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MDV3800-02, NCI-2017-00161, NCT02997176
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MDV3800-01, NCI-2017-00182, NCT02997163
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MDV3800-14, NCI-2017-00414, NCT03042910
Start Over